Thryv Therapeutics to Participate in the UBS Global Biopharma Conference in London
Advancing Precision SGK1 Inhibitors at the Intersection of Electrical and Structural Heart Disease SAN FRANCISCO, Nov. 12, 2026 /PRNewswire/ -- Thryv Therapeutics Inc., a clinical-stage biotechnology company developing precision therapies for inherited channelopathies, cardiometabolic...